Introduction

Semaglutide, a groundbreaking pharmaceutical compound with the CAS number 910463-68-2, has emerged as a pivotal player in the treatment of type 2 diabetes and obesity. This article delves into the intricate details of Semaglutide, exploring its functional mechanisms, technical specifications, applications, and the company behind its production. Additionally, we incorporate insights from the National Institute of Standards and Technology (NIST) to underscore the importance of precision in pharmaceutical development.

Product Overview

Semaglutide is a synthetic peptide designed to mimic the actions of glucagon-like peptide-1 (GLP-1), a hormone critical for regulating blood sugar levels. By binding to GLP-1 receptors, it enhances insulin secretion, suppresses glucagon release, and slows gastric emptying, thereby improving glycemic control in adults with type 2 diabetes (T2DM). Furthermore, its role in weight management has garnered significant attention, as it promotes satiety and reduces caloric intake.

Technical Specifications

The following table provides a detailed overview of Semaglutide's technical parameters:

Parameter	Details
CAS No.	910463-68-2
Product Name	Semaglutide
Synonyms	Sermaglutide, Semaglutide fandachem, Semaglutide impurity, Sermaglutide USP/EP/BP, etc.
Molecular Formula	C187H291N45O59
Formula Weight	4113.57754
Appearance	White to off-white solid powder
Purity	>98%
Storage	Dry, dark, and at 0–4°C (short term) or -20°C (long term)
Solubility	Soluble in DMSO
Shipping Condition	Ambient temperature as non-hazardous chemical

Functional Mechanism

Semaglutide's efficacy stems from its structural modifications compared to liraglutide, a similar GLP-1 receptor agonist. The inclusion of two key changes—replacement of Gly with 2-aminoisobutyric acid (Aib) at position 2 and the attachment of an 18-carbon fatty acid moiety—enhances its stability and binding affinity. These modifications increase resistance to dipeptidyl peptidase-4 (DPP-4), an enzyme that degrades GLP-1, and improve its half-life in humans to approximately seven days (NIST). This extended half-life allows for once-weekly dosing, improving patient compliance.

Applications

Semaglutide's applications span multiple therapeutic areas:

• Weight Loss: Clinical trials have demonstrated its effectiveness in reducing body weight by enhancing satiety and reducing food intake (NIST).
• Anti-Diabetic Therapy: It is FDA-approved for T2DM management, offering improved glycemic control when combined with diet and exercise.
• Alzheimer's Disease Research: Emerging studies suggest potential neuroprotective effects, though further research is needed (NIST).

Company Profile: Hebei Weimiao Import and Export Trade Co., Ltd.

Based in Hebei, China, Hebei Weimiao Import and Export Trade Co., Ltd. specializes in the production and supply of high-quality pharmaceutical intermediates. The company is renowned for its commitment to quality, adhering to stringent international standards. With a focus on innovation and customer satisfaction, Hebei Weimiao has established itself as a reliable supplier in the pharmaceutical intermediates market.

Why Choose Hebei Weimiao?

Hebei Weimiao distinguishes itself through several key advantages:

• Quality Assurance: Rigorous third-party testing ensures product purity and safety.
• Competitive Pricing: The company offers cost-effective solutions without compromising on quality.
• Flexible Ordering: Minimum order quantities (MOQs) are flexible, accommodating both small and large-scale purchases.
• Global Reach: The company ships worldwide, ensuring timely delivery through reliable logistics partners.

FAQs

Q: Are you a trading company or manufacturer?
A: We are a manufacturer.

Q: Do you provide samples?
A: Yes, samples are available for evaluation before bulk production.

Q: What payment terms do you accept?
A: Western Union, T/T, BTC, and Alibaba.

Q: What is your delivery time?
A: Delivery occurs after receipt of full payment.

Conclusion

Semaglutide represents a significant advancement in the treatment of T2DM and obesity, offering a unique combination of efficacy and convenience. Its development and commercialization by Hebei Weimiao Import and Export Trade Co., Ltd. highlight the company's dedication to innovation and quality. As research continues to uncover its potential in areas like Alzheimer's disease, Semaglutide's impact on global healthcare is poised to grow. For those seeking reliable active pharmaceutical intermediates, Hebei Weimiao stands as a trusted partner.

References

National Institute of Standards and Technology (NIST). (2025). Advancements in Pharmaceutical Standards and Research. Retrieved from https://www.nist.gov/